Susquehanna Reiterates Neutral on RPC, Maintains $50 Price Target
Susquehanna analyst Charles Minervino reiterates RPC (NYSE:RES) with a Neutral and maintains $50 price target.
Susquehanna Reiterates Positive on Halliburton, Maintains $57 Price Target
Susquehanna analyst Charles Minervino reiterates Halliburton (NYSE:HAL) with a Positive and maintains $57 price target.
Susquehanna Reiterates Neutral on NOW, Maintains $14 Price Target
Susquehanna analyst Charles Minervino reiterates NOW (NYSE:DNOW) with a Neutral and maintains $14 price target.
Benchmark Reiterates Buy on Beauty Health, Maintains $23 Price Target
Benchmark analyst Bruce Jackson reiterates Beauty Health (NASDAQ:SKIN) with a Buy and maintains $23 price target.
Stephens & Co. Reiterates Overweight on Avid Bioservices, Maintains $22 Price Target
Stephens & Co. analyst Jacob Johnson reiterates Avid Bioservices (NASDAQ:CDMO) with a Overweight and maintains $22 price target.
Stephens & Co. Reiterates Equal-Weight on Amedisys, Maintains $103 Price Target
Stephens & Co. analyst Scott Fidel reiterates Amedisys (NASDAQ:AMED) with a Equal-Weight and maintains $103 price target.
RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target
RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
RBC Capital Reiterates Sector Perform on Paysafe, Maintains $36 Price Target
RBC Capital analyst Daniel Perlin reiterates Paysafe (NYSE:PSFE) with a Sector Perform and maintains $36 price target.
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics – 1-for-18 Reverse Stock Split
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy, 1-for-18 reverse stock split.
RBC Capital Reiterates Sector Perform on BioCryst Pharma, Maintains $10 Price Target
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Sector Perform and maintains $10 price target.